{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T01:20:33Z","timestamp":1778289633104,"version":"3.51.4"},"reference-count":24,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3566,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pediatric bipolar diorder is a serious neuropsychiatric disorder asociated with high levels of morbidity and disabilty.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This is a systematic chart review of all outpatient youth with the diagnosis of bipolar disorder and bipolar spectrum disorder treated with aripiprazole either alone or as add-on to ongoing treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Medical records were reviewed to identify all subjects with bipolar and bipolar spectrum disorder prescribed aripiprazole in our clinic. During the chart review, the Clinical Global Impression scale was completed by the treating clinicians to determine usefullness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-one youths (mean age\u00b1SD: 11.4\u00b13.5 years) with bipolar spectrum disorder who had been treated with aripiprazole were identified. These children received a mean daily dose of aripiprazole 16.0\u00b17.9 mg over an average of 4.6 months. Using a Clinical Global Impression-Improvement scale score of &lt;2 (very much\/much improved) to define robust improvement, 71% showed improvement in manic symptoms. Treatment with aripiprazole was well tolerated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study suggests that aripiprazole may be a useful and well-tolerated treatment for youth with bipolar disorder and it supports the need for controlled clinical trials of this compound in juvenile mania.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852900019489","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T17:35:06Z","timestamp":1444757706000},"page":"141-148","source":"Crossref","is-referenced-by-count":67,"title":["Aripiprazole in the Treatment of Pediatric Bipolar Disorder: A Systematic Chart Review"],"prefix":"10.1017","volume":"10","author":[{"given":"Joseph","family":"Biederman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ann","family":"McDonnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Aleardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Falzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Mick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900019489_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199510000-00014"},{"key":"S1092852900019489_ref023","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199705000-00020"},{"key":"S1092852900019489_ref022","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199705000-00021"},{"key":"S1092852900019489_ref021","first-page":"249","article-title":"Risperidone in the treatment of mania","volume":"57","author":"Tohen","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"S1092852900019489_ref020","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v59n1111"},{"key":"S1092852900019489_ref019","first-page":"809","article-title":"Rating scales and checklists for child psychopharmacology","volume":"21","author":"Conners","year":"1985","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900019489_ref018","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"S1092852900019489_ref017","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.9.1651"},{"key":"S1092852900019489_ref016","volume-title":"Micromedex Healthcare Series","year":"1974"},{"key":"S1092852900019489_ref015","first-page":"25","article-title":"Aripiprazole: the latest antipsychotic","volume":"38","author":"McRae","year":"2003","journal-title":"Intern Drug Ther Newsletter"},{"key":"S1092852900019489_ref014","first-page":"27","article-title":"Use of quetiapine in children and adolescents","volume":"63","author":"Findling","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"S1092852900019489_ref002","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.927"},{"key":"S1092852900019489_ref004","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-5618.2000.20309.x"},{"key":"S1092852900019489_ref010","first-page":"9","volume-title":"Abstracts of Fifth Annual International Conference on Bipolar Disorder","author":"Brecher","year":"2003"},{"key":"S1092852900019489_ref006","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.741"},{"key":"S1092852900019489_ref011","doi-asserted-by":"publisher","DOI":"10.1089\/10445460152595568"},{"key":"S1092852900019489_ref008","first-page":"251","article-title":"Tardive and withdrawal dyskinesia in autistic children: a prospective study","volume":"24","author":"Campbell","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"S1092852900019489_ref001","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00911-2"},{"key":"S1092852900019489_ref012","doi-asserted-by":"crossref","unstructured":"Biederman J . Open-label study of risperidone I children with bipolar disorder. Abstract presented at: annual meetiong of European College of Neuropsychology. 2003; Prague, Czech Republic.","DOI":"10.1016\/S0924-977X(03)92032-3"},{"key":"S1092852900019489_ref013","doi-asserted-by":"publisher","DOI":"10.1089\/104454603321666216"},{"key":"S1092852900019489_ref003","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199507000-00010"},{"key":"S1092852900019489_ref005","article-title":"Further evidence of unique developmental phenotypic correlates of pediatric bipolar disorder: findings from a large sample of clinically referred preadolescent children assessed over the last 7 years","author":"Biederman","journal-title":"J Affect Disord"},{"key":"S1092852900019489_ref007","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.9.841"},{"key":"S1092852900019489_ref009","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.7.1146"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900019489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T14:28:37Z","timestamp":1557152917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900019489\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["S1092852900019489"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900019489","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2]]}}}